T-DXd
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer, Metastatic Cancer
Trial Timeline
Jan 5, 2024 → Jan 17, 2028
NCT ID
NCT06174987About T-DXd
T-DXd is a phase 3 stage product being developed by Daiichi Sankyo for Advanced Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06174987. Target conditions include Advanced Cancer, Metastatic Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06174987 | Phase 3 | Recruiting |
Competing Products
20 competing products in Advanced Cancer